Back to Webinars

A Journey into the Unknown:

Wednesday, June 22, 2016
8:21am PDT
1 hour and 3 minutes

During this presentation, you will:

  • Gain exposure to NGS panel trends observed by Ambry Genetics
  • Examine pathogenic results observed in patients not meeting diagnostic criteria for single gene testing or a hereditary cancer syndrome
  • Compare the strengths, limitations, and differences between multi-gene panels and whole exome sequencing
  • Assess the utility of whole exome sequencing in suspected hereditary cancer syndromes
  • Review novel gene analysis interpretation and positive results attributed to previously uncharacterized genes.
57dee625eacec
Emily Dalton
Director, Genomic Science Liaisons
Emily Dalton is the Director of the Genomic Science Liaison team at Ambry Genetics, where she oversees a field-based team of clinical and technical experts in Ambry’s offerings. During her tenure at Ambry, Emily has presented at a number of domestic and international conferences and cultivated research collaborations with major academic medical centers.  Prior to […]

Emily Dalton is the Director of the Genomic Science Liaison team at Ambry Genetics, where she oversees a field-based team of clinical and technical experts in Ambry’s offerings. During her tenure at Ambry, Emily has presented at a number of domestic and international conferences and cultivated research collaborations with major academic medical centers.  Prior to joining Ambry Emily spent four years as a cancer genetic counselor at the Dana-Farber Cancer Institute in Boston, MA and received her Master’s in Genetic Counseling from the Boston University School of Medicine.

57fe32bd85c63
Michael Osborne
Sr. Genetic Specialist
Senior General Genetic Specialist

Senior General Genetic Specialist

Brigette Tippin Davis
Chief Operating Officer